ReviewExpert opinion on investigational drugs2022

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.

Linjie Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.